The nuclear receptor PPARa is activated by drugs to treat human disorders of lipid metabolism. Its endogenous ligand is unknown. PPARa-dependent gene expression is impaired with inactivation of fatty acid synthase (FAS), suggesting that FAS is involved in generation of a PPARa ligand. Here we demonstrate the FAS-dependent presence of a phospholipid bound to PPARa isolated from mouse liver. Binding was increased under conditions that induce FAS activity and displaced by systemic injection of a PPARa agonist. Mass spectrometry identified the species as 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Knockdown of Cept1, required for phosphatidylcholine synthesis, suppressed PPARa-dependent gene expression. Interaction of 16:0/18:1-GPC with the PPARa ligandbinding domain and coactivator peptide motifs was comparable to PPARa agonists, but interactions with PPARd were weak and none were detected with PPARg. Portal vein infusion of 16:0/18:1-GPC induced PPARa-dependent gene expression and decreased hepatic steatosis. These data suggest that 16:0/18:1-GPC is a physiologically relevant endogenous PPARa ligand.
INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) constitute a subfamily of nuclear receptors with three current members: PPARa, PPARg, and PPARd. Each receptor appears to modulate pathways at the interface between intermediary metabolism and inflammation, making them physiologically and clinically relevant (Bensinger and Tontonoz, 2008) . PPARa is activated by fibrate drugs to lower triglycerides and raise HDL (Barter and Rye, 2008) , PPARg is targeted by glitazones to treat diabetes (Yki-Jarvinen, 2004) , and pharmacological activation of PPARd appears to improve several metabolic parameters in humans (Riserus et al., 2008) . PPARs are ligand-activated receptors that heterodimerize with RXR, bind to response elements in target genes, and alter coactivator/corepressor dynamics to induce transcription. Fatty acids, especially if polyunsaturated, are thought to be preferred PPAR ligands, but a wide variety of lipids (Forman et al., 1997; Kliewer et al., 1997; Krey et al., 1997; Yu et al., 1995) have been implicated in PPAR activation including saturated fatty acids, fatty acyl-CoA species, eicosanoids (prostaglandins, leukotrienes, and HETEs), oxidized fatty acids, and oxidized phospholipids. No endogenous PPAR ligand has been identified.
PPARa is expressed at high levels in liver where it promotes fatty acid oxidation, ketogenesis, lipid transport, and gluconeogenesis (Bernal-Mizrachi et al., 2003; Reddy and Hashimoto, 2001) . Systemic levels of free fatty acids change with nutritional status, making PPARa an attractive candidate sensor of energy balance that might respond to fatty acids by accelerating their metabolism. This would require that PPARa, a nuclear protein, be exposed to concentrations of fatty acids that reflect those outside the cell. A simple diffusion gradient for these lipids in the hepatocyte is unlikely to exist because fatty acids crossing the plasma membrane undergo addition of an acyl-CoA group, leading to a myriad of potential fates including storage in lipid droplets, synthesis of phospholipids, incorporation into intracellular organelles or the external plasma membrane, transport into mitochondria for beta oxidation, association with the ER/Golgi for lipoprotein assembly, and others. This scheme suggests that fatty acids are chaperoned from the extracellular environment to the nucleus to activate PPARa, or that another entity reflecting nutritional status is involved in generating the endogenous ligand.
No chaperone has emerged for the PPARa ligand. FABP4, which binds fatty acids, has been implicated in shuttling ligand to another family member, PPARg (Ayers et al., 2007) . FABP1, an abundant protein in liver that binds a broad range of fatty acids, might serve a similar function for PPARa. But PPARa-dependent genes are expressed appropriately in FABP1 null mice (Newberry et al., 2003) , indicating that FABP1 probably does not present ligand to PPARa.
There is evidence that a nutritionally responsive entity may generate the endogenous PPARa ligand. Fatty acid synthase (FAS) catalyzes the first committed step in fatty acid biosynthesis, utilizing acetyl-CoA, malonyl-CoA, and NADPH to generate mostly the saturated fatty acid palmitate (Semenkovich, 1997) . Liver-specific inactivation of FAS results in mice with decreased PPARa-dependent gene expression and a phenotype resembling PPARa deficiency (Chakravarthy et al., 2005) . The phenotype is reversed and gene expression rescued after pharmacologic activation of PPARa. This phenomenon is not limited to the liver. Selective inactivation of FAS in the hypothalamus impairs PPARa-dependent gene expression and alters feeding behavior (Chakravarthy et al., 2007) . Both are corrected after hypothalamic infusion of a PPARa activator. It thus appears that FAS, known to be regulated by nutrition, is required in some tissues to generate the endogenous ligand for PPARa.
To characterize that ligand, we developed a strategy based on purifying a tagged PPARa molecule from the livers of mice with or without expression of FAS. This strategy was used to test the hypothesis that de novo lipid biosynthesis generates a physiologically relevant endogenous ligand for PPARa.
RESULTS
Fatty acid synthase knockout in liver (FASKOL) mice have impaired PPARa-dependent gene expression that is rescued after pharmacological activation of PPARa (Chakravarthy et al., 2005) . These mice were crossed with PPARa null mice to eliminate the possibility of ligand competition between adenovirally transduced PPARa and endogenous PPARa. Figure 1A (F) Immunoprecipitation (IP) and immunoblot (IB) analysis in livers of WT and FASKOL mice on a PPARa null background infected with adenoviruses encoding GFP alone (AdGFP) or FLAG-tagged PPARa (AdFLAG-PPARa). Nuclear fractions were immunoprecipitated with FLAG antibodies and immunoblotted with either FLAG antibody (top) or PPARa antibody (middle). Crude liver lysates were immunoblotted with actin antibody (bottom). Blots are representative of >12 independent experiments.
background was verified by demonstrating decreased FAS protein ( Figure 1B ) and enzyme activity ( Figure 1C ) in the livers of FASKOL mice. The FAS substrate malonyl-CoA accumulated in FASKOL livers ( Figure 1D ), confirming decreased enzyme activity. Figure 1E depicts our strategy for detecting the endogenous PPARa ligand. Mice were treated with an adenovirus directing expression of a FLAG-tagged PPARa under conditions that do not induce appreciable liver inflammation as reflected by normal liver function tests (Table S1 available online). Our reconstitution method has been shown to achieve levels of PPARa comparable to wild-type mice (Bernal-Mizrachi et al., 2003) . Reconstitution was followed by affinity capture (utilizing an antibody recognizing the FLAG epitope) of PPARa under conditions (no detergent or high salt elution buffers) unlikely to disrupt the ligand/nuclear factor interaction. This yielded a dominant PPARa band on protein-stained gels (not shown). Figure 1F shows affinity matrix eluates subjected to immunoprecipitation followed by immunoblotting. These results confirm the absence of endogenous PPARa (lanes 1 and 3) and indicate that the yield of tagged PPARa from liver was similar in mice with and without expression of FAS (lanes 2 and 4).
Affinity matrix eluates (with equal protein content) of nuclear fractions from mice treated with AdGFP (as a control) or AdPPARa in the presence (WT/ PPARa À/À ) or absence (FASKOL/ PPARa À/À ) of FAS were subjected to mass spectrometric analysis of extracted lipids. No appreciable lipid signal was detected from GFP eluates (Figures 2A, 2C , 2E, and 2G for a portion of the phospholipid spectra; triglyceride and fatty acid signals were also essentially absent, data not shown), suggesting that nonspecific binding of lipids to GFP protein was minimal. We did not detect fatty acids or triglycerides bound to PPARa that were consistent with a FAS-dependent ligand. FAS dependence was assessed by isolating PPARa from mice with and without FAS deficiency and from animals fed chow as well as a high-carbohydrate, zero-fat diet (ZFD), as indicated by the fact that carbohydrates induce FAS expression. PPARa triglyceride binding was increased in both wild-type and FAS-deficient livers ( Figure S1 ), and this was more pronounced in the latter, consistent with the hepatic steatosis that occurs with zero-fat diet feeding in FASKOL mice. There were no genotype or diet effects on binding of PPARa to any molecular species of phosphatidylethanolamine or phosphatidylinositol ( Figure S2 ), common fatty acids ( Figure S3 ), or lysophosphatidylcholine ( Figure S4 ).
Lipid analyses revealed only one peak that was FAS dependent. It was observed in positive ion phospholipid spectra. Material represented by a peak with mass to charge ratio (m/z) of 766.5 bound to PPARa purified from livers expressing FAS (arrow, Figure 2B ) and its abundance was significantly decreased in PPARa purified from FAS-deficient livers (arrow, Figure 2D ). The abundance of m/z 766.5 increased in PPARa purified from WT mice fed a diet high in carbohydrates (ZFD) (arrow, Figure 2F , compare m/z 766 to m/z 764 in Figures 2F and 2B) but remained low with FAS deficiency (arrow, Figure 2H ). Quantitation of relative peak abundance in independent experiments is presented in Figure 2I . Increased association of the material represented by the ion at m/z 766 with PPARa after high-carbohydrate feeding and its decreased detection with FAS deficiency indicate that this material is FAS related.
Tandem mass spectrometry ( Figure 3 ) identified this material as the phospholipid molecular species 1-palmitoyl-2-oleoly-snglycerol-3-phosphocholine (16:0/18:1-GPC). Figure 3A Figure 3B indicate that palmitate and oleate are the sn-1 and sn-2 substituents, respectively, because the abundance of the ion reflecting loss of trimethylamine plus the sn-1 substituent always exceeds that of the ion reflecting loss of trimethylamine plus the sn-2 substituent . Figure 3C shows a diagram of the putative PPARa ligand based on these mass spectra. If 16:0/18:1-GPC is an endogenous PPARa ligand, it should be possible to competitively inhibit its binding with a known ligand in living mice. This was demonstrated by administering 50 mg/g of Wy14,643, a dose known to rapidly activate PPARa (Chakravarthy et al., 2005) , at time 0, followed by isolation of PPARa-bound lipids from the mouse livers. The putative ligand was displaced from PPARa within minutes of treatment with the known agonist, both in the setting of chow ( Figures 4A-4D ) and zero-fat diet ( Figures 4E-4H ) feeding. Note the rapid decrease in abundance for m/z 766 (representing 16:0/18:1-GPC) relative to the invariant m/z 764 (16:0/18:2-GPC) and the increased abundance of m/z 766 at 0 min with zero-fat diet compared to chow diet. Quantitation of relative peak abundance for independent experiments is presented in Figure 4I .
Although the rapid decline in signal with Wy14,643 treatment could represent displacement of endogenous ligand from its binding site on PPARa, it is also possible that lipid loss could represent accelerated metabolism because Wy14,643 activates lipid oxidation. To distinguish between these two possibilities, we repeated the in vivo competitive inhibition experiment by using a PPARa molecule with a defective DNA binding domain ( Figure 5 ). This protein, DDBD-PPARa, should retain ligand binding yet be incapable of increasing transcriptional programs promoting lipid metabolism. Two cysteine residues conserved in all PPAR family members were mutated to alanines in PPARa ( Figure 5A ). Mutation of these residues in PPARd abolishes DNA binding activity (Shi et al., 2002) . Adenoviral expression of this mutated protein resulted in similar levels of protein as wildtype PPARa ( Figure 5B ), and DNA binding was verified to be impaired with this mutant (DDBD in Figure 5C ). Mice were treated with AdGFP (as a control) or Ad-DDBD-PPARa in the presence (WT/PPARa involving concentration-dependent displacement of radiolabeled Wy14,643. Binding constants of 16:0/18:1-GPC, 16:0/ 18:2-GPC, and 18:1/18:1-GPC for PPARa were identical and, as expected, indicated a lower affinity of these phospholipids for PPARa than Wy14,643 ( Figure S5 ). These results are consistent with the notion that the in vivo displacement of 16:0/ 18:1-GPC by Wy14,643 represents competition of a higheraffinity synthetic ligand for an endogenous ligand.
The binding of 16:0/18:1-GPC to PPARa was decreased in the absence of FAS and significantly increased under conditions (high-carbohydrate feeding) that induce FAS activity (see Figure 2I ), suggesting that FAS is involved in the generation of this ligand. Total hepatic nuclear concentrations of 16:0/18:1-GPC, 16:0/18:2-GPC, and 18:1/18:1-GPC were assayed by mass spectrometry under fed and fasting conditions (Table  S2) . 16:0/18:1-GPC and 16:0/18:2-GPC tended to increase with fasting, but these differences were not significant. These assays represent measurements of the total content of a particular phospholipid in the nucleus, not phospholipid bound to PPARa or phospholipid available for signaling. Relevant endogenous ligands should fluctuate during metabolic transitions but current techniques require use of the entire nucleus, which includes a considerable mass of structural GPCs comprising nuclear membranes. The predominant mass of structural GPCs likely overwhelms any changes in the smaller mass of GPCs that might serve a signaling role by liganding nuclear receptors. Assaying the entire nucleus did, however, allow the determination of the relative abundance of 16:0/18:1-GPC. The contribution of 16:0/18:1-GPC to total nuclear phosphatidylcholine in mouse liver was 11.4% ± 0.6% and its contribution to total nuclear phospholipids was 4.4% ± 1.2%. Ligand-dependent activation of PPARa induces expression of genes involved in fatty acid metabolism such as acyl-CoA oxidase and the liver isoform of carnitine palmitoyl transferase 1 (Acox1 and Cpt1a). Incubation of cultured mouse hepatoma cells with exogenous 16:0/18:1-GPC (the FAS-dependent phosphatidylcholine species) increased expression of both Acox1 and Cpt1a to a similar degree as equimolar amounts of the known PPARa activator Wy14,643 ( Figure S6 ). However, the link between FAS and PPARa is most likely to be mediated by effects on endogenous phosphatidylcholine synthesis, which occurs mostly through the Kennedy pathway ( Figure 6A ). Endogenous synthesis involves the successive action of choline kinase (CK) and CTP:phosphocholine cytidylyltransferase (CCT) to yield CDP-choline (Kent, 2005) . This substrate reacts with diacyglycerol (DAG) to yield phosphatidylcholine (PtdCho) through the action of one of two enzymes, choline phosphotransferase 1 (ChPT1), found in the Golgi, and cholineethanolamine phosphotransferase-1 (CEPT1), found in the nucleus as well as the ER (Henneberry et al., 2002) . siRNA-mediated knockdown of these enzymes was achieved in cultured mouse hepatoma cells ( Figure 6B ), followed by assessment of PPARadependent genes. Inactivation of ChPT1, the Golgi enzyme, had no effect on Acox1 or Cpt1a ( Figure 6C ). However, knockdown of CEPT1, the nuclear/ER enzyme, decreased PPARa-dependent genes, an effect that was rescued by exogenous 16:0/18:1-GPC ( Figure 6D) , consistent with the notion that endogenous 16:0/ 18:1-GPC activates PPARa and that FAS-dependent 16:0/18:1-GPC is an endogenous PPARa ligand.
Two additional pieces of evidence support the link between CEPT1 and induction of PPARa-dependent genes. Overexpression of CEPT1 in hepatoma cells increased expression of Acox1 and Cpt1a ( Figure 6E ). We also generated an adenovirus expressing an shRNA for CEPT1. Treatment of living mice with this virus decreased Cept1 expression in liver ( Figure 6F, top) . Livers with decreased Cept1 expression were pale appearing and had increased Oil Red O staining (insets). This intervention resulted in decreased expression of the PPARa-dependent genes Acox1 and Cpt1a ( Figure 6F, bottom) .
Luminescent proximity (AlphaScreen) assays showed that equimolar amounts of 16:0/18:1-GPC and the known potent PPARa activator GW7647 exhibited similar patterns of interaction with the PPARa ligand binding domain (LBD) and a series of coactivator peptides ( Figure 6G ). Nearly identical interaction signals with the PPARa LBD were also seen when equimolar amounts of Wy14,643 and 16:0/18:1-GPC were compared (data not shown). As compared to the PPARd activator GW0742 (Figure 6H ), interactions between 16:0/18:1-GPC and the PPARd LBD were weak, and no signal was detected with the PPARg LBD as compared to the positive control rosiglitazone ( Figure 6I ).
To provide in vivo evidence that 16:0/18:1-GPC serves as a PPARa endogenous hepatic ligand, we implanted catheters in the portal veins of mice, infused this phosphatidylcholine species or vehicle over several days, fasted the animals (while continuing the infusions), then isolated their livers for assays of fat content as well as gene expression. Direct portal vein infusion was prompted by preliminary results showing that intraperitoneal administration of 16:0/18:1-GPC had no effect (data not shown). In additional preliminary experiments, kinetic analyses of radiolabeled phosphatidylcholine showed selective nuclear enrichment within minutes of portal vein administration (Figure S7) . The appearance of the catheter in the portal vein (pvcath) is shown in Figure 7A . Our treatment protocol is shown in Figure 7B . After recovering from catheter placement, mice were started on a zero-fat diet (ZFD) and treated with thrice-daily infusions of phosphatidylcholine or vehicle between days 4 and 9 followed by a prolonged fast (while continuing the infusions). Fasting causes fatty liver in mice, an effect that is amplified in PPARa null mice. Fat staining of liver is shown in Figure 7C and liver triglyceride quantified in Figure 7D . Lipid content of PPARa-deficient mice was increased as compared to controls and unaffected by phosphatidylcholine infusion. Fat content was decreased in control (C57/BL6) mice with infusion of 16:0/ 18:1-GPC as compared to vehicle. The PPARa-dependent genes Acox1 and Cpt1a were increased by 16:0/18:1-GPC in control mice but not in PPARa-deficient mice ( Figure 7E ).
DISCUSSION
PPARs are targets of drugs in use and in development to treat disease, and they modulate metabolic and inflammatory pathways by responding to nutritional signals through ligand activation of transcription. No authentic endogenous PPAR ligand, the molecule occupying the nuclear receptor binding site in vivo while the receptor is actively driving transcription, has been identified. Here we demonstrate PPARa binding of a discrete phospholipid, 16:0/18:1-GPC, in mammalian liver in the presence of FAS, when PPARa is active, but not in the absence of FAS, when PPARa is not. This molecule was displaced from PPARa in vivo with a pharmacological ligand, inhibiting its biosynthesis in cells and living mice disrupted PPARadependent gene expression and infusing it directly into mouse liver, altered hepatic lipid metabolism in a PPARa-dependent fashion. These results suggest that this particular phosphatidylcholine species is a physiologically relevant endogenous PPARa ligand in liver.
There is precedent for the interaction of phospholipids with nuclear receptors. The crystal structure of the insect homolog of mammalian RXR includes copurified phospholipid (Billas et al., 2001; Clayton et al., 2001 ). Structures of the ligand binding domains of two orphan receptors, SF-1 and LRH-1, include electron density patterns representing phospholipids (Krylova et al., 2005; Li et al., 2005; Ortlund et al., 2005) . In contrast to PPARa, which forms heterodimers with RXR and is clearly ligand activated, SF-1 and LRH-1 bind to DNA as monomers and it is not known whether the ligands for these receptors are involved in dynamic regulation of their activity (Forman, 2005) . Oxidized phospholipids, especially those derived from modified lowdensity lipoprotein particles through the action of phospholipases or lipoxygenases, have been implicated in the activation of PPARa and PPARg (Davies et al., 2001; Delerive et al., 2000; Lee et al., 2000) .
Our current results show that the phosphatidylcholine molecular species 16:0/18:1-GPC binds PPARa at an activating ligand binding site (reflected by its displacement with a synthetic PPARa ligand in vivo) when FAS enzyme activity is present. 16:0/18:1-GPC is the only FAS-dependent phosphatidylcholine species we identified bound to PPARa in vivo. However, two other phosphatidylcholine species, 16:0/18:2-GPC and 18:1/ 18:1-GPC, were also copurified with tagged PPARa from liver, and their interactions with the PPARa ligand binding domain in vitro ( Figure S5 ) were indistinguishable from those of 16:0/ 18:1-GPC. The failure to discriminate between these three GPCs in vitro may be due to differential interactions between ligands and ligand-binding domains in vitro as opposed to ligands and full-length receptors in vivo. 16:0/18:2-GPC and 18:1/18:1-GPC, but not 16:0/18:1-GPC, remained bound to PPARa in the absence of hepatic FAS, a condition characterized by a striking decrease in PPARa-dependent gene expression. Their association with the receptor in the absence of appropriate activation of gene expression suggests that the binding of 16:0/ 18:2-GPC and 18:1/18:1-GPC is not sufficient for receptor activation, but we cannot exclude the possibility that the presence of these additional species may be necessary for receptor activation. In AlphaScreen assays, 16:0/18:1-GPC interacted with PPARa but not PPARg, suggesting that this species does not bind nonspecifically to PPARs and consistent with data showing that 16:0/18:1-GPC does not interact with the ligand-binding domains of PPARg, SF-1, or LRH-1 (Krylova et al., 2005) . One interpretation of our findings is that FAS, which synthesizes predominantly the saturated fatty acid palmitate (16:0), preferentially channels newly synthesized palmitate through diacylglycerol to the site of phosphatidylcholine synthesis for generation of the PPARa ligand. Previous data also link fatty acid synthesis and phosphatidylcholine synthesis. In cultured cells, SREBPs stimulate the synthesis of phosphatidylcholine (but not other phospholipids), and this effect is attenuated by the FAS-inhibitor cerulenin (Ridgway and Lagace, 2003) . Figure 7F shows how fatty acid synthesis, phosphatidylcholine synthesis, and PPARa signaling appear to be related based on the current findings.
In the current work, addition of 16:0/18:1-GPC to cultured cells increased PPARa-dependent gene expression ( Figure S6 ), its addition rescued PPARa-dependent gene expression when endogenous synthesis of phosphatidylcholine was interrupted ( Figure 6D ), and its infusion directly into the portal vein of living mice increased PPARa-dependent genes and corrected fasting-induced steatosis only in the presence of PPARa ( Figures  7A-7E) . These experiments support the concept that this GPC species activates PPARa, but they do not show that a circulating form of this lipid reports nutritional status. In fact, how altering extracellular concentrations of a charged phospholipid species might affect nuclear events is unknown, although there is evidence that certain extracellular phospholipids have direct access to the nuclear receptor PPARg (Davies et al., 2001) .
Our results showing that portal vein infusion results in nuclear before cytoplasmic accumulation ( Figure S7 ) are consistent with an uncharacterized conduit for phospholipids to the nucleus. Because the portal vein drains the intestine, the anatomic origin of nutrients, the results also suggest that providing a GPC ligand in the diet, if it were able to access the portal vein at sufficient concentrations, could activate hepatic PPARa. The method of infusion, utilizing the portal vein, is likely important. FASKOL mice have elevated circulating levels of fatty acids (in the peripheral venous circulation) that contribute to the hepatic steatosis of these animals (Chakravarthy et al., 2005) . Curiously, these fatty acids (so abundant that they cause fatty liver) from the periphery (that we have referred to as ''old '' fat as opposed to ''new'' fat from de novo lipogenesis or diet) are unable to activate PPARa, suggesting (based on the current work) that they are unavailable for GPC synthesis. Lipids from the periphery enter the liver via the hepatic artery whereas those from the diet enter via the portal vein. The hepatic artery and portal vein comprise anatomically distinct regions of the portal triad, and it is possible that hepatocytes in those different segments respond differently to lipid signals.
Although the infusion studies provide proof of principle that 16:0/18:1-GPC can affect liver biology in a PPARa-dependent manner, they are not directly germane to the central finding of this paper that the intracellular enzyme FAS is linked to the generation of a physiologically relevant endogenous ligand for PPARa. However, the infusion studies represent grounds for future research involving portal vein infusions as well as dietary supplementation with GPCs labeled at different substituents to further pursue the notion that an externally provided GPC can reach PPARa intact.
Modulating phospholipids is also complicated by remodeling, a process identified by Lands (Lands, 1960) that results in the rearrangement of fatty acid substituents. Not all of the responsible enzymes have been identified, but PPARa activation induces the expression of a recently discovered lysophosphatidylcholine acyltransferase (LPCAT3) in liver that remodels the sn-1 and sn-2 fatty acid substituents (Zhao et al., 2008) and might represent a mechanism for dampening phosphatidylcholine-mediated activation of PPARa.
Phosphatidylcholine is ubiquitous in the cell and comprises a substantial proportion of the nuclear volume. It would have a limited capacity to regulate PPARa if high nuclear concentrations ensured constant occupation of the ligand binding site, but the putative PPARa ligand we identified, 16:0/18:1-GPC, is a minor PtdCho species in liver as shown by the current work (Results) and previous work , consistent with a signaling role for this molecule. Conversely, 16:0/18:1-GPC is the most abundant PtdCho in brain , raising the possibility that a different PtdCho species may activate PPARa in this tissue.
Both PPARa activation and phosphatidylcholine are thought to be anti-inflammatory (Cuzzocrea et al., 2004; Li et al., 2006; Straus and Glass, 2007; Stremmel et al., 2007; Treede et al., 2007) . Based on our findings of a discrete PtdCho molecular species serving as a hepatic ligand for PPARa, tissue-specific phospholipid ligands, either induced endogenously or perhaps provided in the diet, could modify inflammatory processes so that off-target side effects are minimized.
EXPERIMENTAL PROCEDURES Animals and Reagents
Animal protocols were approved by the Washington University Animal Studies Committee. Mice were genotyped using previously described primer sets (Bernal-Mizrachi et al., 2003; Chakravarthy et al., 2005) and fed either chow (Purina 5053) or a zero-fat diet (ZFD) (Harlan Teklad, TD03314). Experiments were performed at 16-20 weeks of age to allow for maximal effects of albumin-Cre. Assays were performed as described (Chakravarthy et al., 2005) . 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine (PC16:0/18:1) and its regioisomer, 1-Oleoyl-2-Palmitoyl-sn-Glycero-3-Phosphocholine (PC18:1/ 16:0) were obtained from Avanti Polar Lipids (Alabaster, AL). Stealth siRNA oligonucleotides for mouse ChPT1 (GGAGGAGCAACAAUGUGGGACUAUA) and CEPT1 (UGGCAGUGAUUGGAGGACCACCUUU) were from Invitrogen (Carlsbad, CA).
Isolation of Tagged PPARa
Freshly harvested livers ($100 mg) were gently homogenized in ice-cold nondetergent hypotonic buffer (10 mM HEPES [pH 7.9], 1.5 mM MgCl 2 , 10 mM KCl, 100 mM DTT, protease and phosphatase inhibitor cocktail). After an additional 10 min incubation in the hypotonic buffer, the homogenate was centrifuged at 8000 3 g at 4 C for 20 min. The pellet was homogenized in ice-cold extraction buffer (10 mM HEPES [pH 7.9], 1.5 mM MgCl 2 , 0.21 M NaCl, 0.2 mM EDTA, 25% (v/v) glycerol, 100 mM DTT, protease and phosphatase inhibitor cocktail), placed on a rotating shaker at 4 C for 1 hr, then centrifuged at 18,000 3 g for 10 min. The supernatant (nuclear fraction) was incubated with anti-FLAG M2-Agarose affinity gel (A2220, Sigma) overnight at 4 C on a rotating shaker. Four washes (50 mM Tris HCl [pH 7.4], 100 mM NaCl, protease and phosphatase inhibitor cocktail) were followed by elution with competition with excess 33 FLAG peptide (F4799, Sigma; 150 ng/ml). An aliquot of the complex was processed for immunoblotting; the remainder was transferred to methanol/chloroform and processed for mass spectrometry.
Electrospray Ionization Mass Spectrometry
Phosphatidylcholine (GPC), lysophosphatidylcholine (LPC), sphingomyelin (SM), and ceramide (CM) were analyzed as Li + adducts by positive ion ESI/ MS on a Finnigan (San Jose, CA) TSQ-7000 triple-stage quadrupole mass spectrometer with an ESI source controlled by Finnigan ICIS software. Lipids were dissolved in methanol/chloroform (2/1, v/v) containing LiOH (10 pmol/ml), infused with a Harvard syringe pump, and analyzed as described Turk, 2000, 2003) . For tandem MS, precursor ions selected in the first quadrupole were accelerated into a chamber containing argon to induce collisionally activated dissociation, and product ions were analyzed in the final quadrupole. Ramanadham et al., 1998) and their tandem spectra were obtained.
DNA Binding Activity
Cos-7 cells maintained in DMEM containing 10% fetal bovine serum were transiently transfected with 2 mg of wild-type and DBD mutant-PPARa plasmids by using FuGENE6 (Roche) as described (Lodhi et al., 2007) . Nuclear extract DNA binding activity was determined with the PPARa transcription factor assay kit (Cayman Chem, Inc.).
Mouse Hepatocytes
The C57BL/6 mouse hepatoma cell line Hepa 1-6 (ATCC, CRL-1830) was expanded in DMEM with 10% fetal bovine serum. For experiments, cells were cultured to 50%-60% confluence and washed twice with PBS, and the medium was changed to serum-free DMEM supplemented with the various types and concentrations of phosphatidylcholine (sonicated to homogeneity in PBS/1% ethanol/4% fatty acid-free BSA), Wy14,643 (dissolved in 80% PBS/20% DMSO), or vehicle-only solutions. 24 hr later, cells were washed, RNA prepared, and Acox1 and Cpt1a expression levels were determined by quantitative RT-PCR. For siRNA experiments, 50%-60% confluent cells were treated with siRNAs or their scrambled controls (all diluted in PBS) for 72 hr. After the 72 hr siRNA treatment, another set of cells received 16:0/18:1-GPC (with a concentration based on dose-response experiments) for an additional 24 hr. For overexpression of CEPT1, cells were transfected with a vector containing human CEPT1 cloned in the pCMV6-XL4 plasmid (Origene, Rockwell, MD) with Lipofectamine 2000 (Invitrogen). After 24 hr, RNA was isolated.
CEPT1 shRNA Adenovirus pLKO.1 plasmid (TRCN0000103315) encoding mouse Cept1 shRNA under control of the U6 promoter was obtained from Open Biosystems (Huntsville, AL). The shRNA sequence is ccggCCCATCCTATAAACTGAATATctcgagATA TTCAGTTTATAGGATGGGtttttg.
To construct the Cept1 knockdown adenovirus, the shRNA expression cassette from the pLKO.1 plasmid was subcloned into the Dual-Basic adenoviral shuttle vector and recombined with Ad5 (DE1/DE3) vector (Vector Biolabs, Philadelphia, PA). The adenovirus was packaged in HEK293 cells and purified with cesium chloride ultracentrifugation. The knockdown virus or a control adenovirus expressing GFP was administered at 8 3 10 9 PFU in a total volume of 200 ml. On day 5 after injection, animals were sacrificed and livers were harvested.
PPAR Binding Assays
Binding of 16:0/18:1-GPC and known agonists to the ligand binding domain (LBD) of PPARa in the presence of various peptide motifs was determined by AlphaScreen assay (Pioszak and Xu, 2008) . Experiments used 100 nM receptor LBD, purified as 63 His tag fusion proteins (Li et al., 2005) , and 20 nM of N-terminal biotinylated CBP1 peptide or other coactivator peptides in the presence of 5 mg/ml donor and acceptor beads in 50 mM MOPS (pH 7.4), 100 mM NaCl, and 0.1 mg/ml BSA for 90 min at 25 C. Signals were generated in the absence or the presence of ligand. Identical experiments were performed with the PPARd and PPARg LBDs.
Portal Vein Infusion
Portal veins were cannulated as described (Strubbe et al., 1999) . The catheter (0.025 mm OD 3 0.012 mm ID, Braintree Scientific), prefilled with 55% (w/v) polyvinylpyrrolidone (Sigma) in heparin (100 IU/ml saline) to prevent clotting, was anchored to the abdominal wall, and its free end was inserted under the skin and tunneled to a small midline incision slightly distal to the scapula on the back. Body weight and food intake returned to baseline levels (usually by day 3) before experiments. Starting on post-op day 4, animals were fed a zero-fat diet (TD 03314, Harlan Teklad) for 5 days, which induces modest to severe hepatic steatosis in C57BL/6 and PPARa À/À mice, respectively.
During this period, animals received three intraportal infusions a day of either 10 mg/kg phosphatidylcholine (16:0/18:1-GPC) sonicated to homogeneity in a 37 C solution of saline/0.5% ethanol/0.5% fatty acid-free BSA, or vehicle alone, based on appropriate time course and dose-response preliminary experiments (see Supplemental Experimental Procedures). Animals were then fasted for 24 hr, and livers were harvested.
Statistical Analyses
Comparisons were performed with an unpaired, two-tailed Student's t test or analysis of variance (ANOVA). If the overall F was significant for the latter, comparisons between means were made with appropriate post hoc tests.
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